CTOs on the Move

MedPharm

www.medpharm.com

 
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.medpharm.com
  • 4222 Emperor Boulevard Suite 335
    Durham, NC USA 27703
  • Phone: 919.436.4985

Executives

Name Title Contact Details
Dave Haas
Vice President Information Technology Profile
Jon Lenn
Chief Technology Officer and Chief Scientific Officer Profile

Similar Companies

Concerto HealthAI

Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.

ZYUS

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of phyto-therapeutics, commonly known as plant-made solutions. We are committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for our patients.

Cornerstone Family Healthcare

Cornerstone Family Healthcare is a comprehensive Hudson Valley medical care provider, offering urgent care, preventative care, womens health, pediatrics and more.

Advanced Care Scripts

Advanced Care Scripts is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.